Summary

painevent1 Newbie

  • Period The second tryout associated with sorafenib and doxorubicin throughout patients using sophisticated hepatocellular carcinoma soon after condition further advancement on sorafenib.
Offline Offline
Posts:
0 (0 per day)
Karma:
+0/-0
Age:
N/A
Date Registered:
May 09, 2024, 08:09:00 AM
Local Time:
May 20, 2024, 03:22:12 AM
Last Active:
May 09, 2024, 10:55:08 AM
Signature:
The principal aim has been one-year progression-free survival (PFS-1y) charge. The sample measurement ended up being 190 people. Your two-sided leader